03613 TONGRENTANGCM
- 10.460
- -0.020-0.19%
TONGRENTANGCM News
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
Tong Ren Tang Chinese Medicine Appoints CEO
Tong Ren Tang Chinese Medicine (HKG:3613) has appointed Wang Chi as its new chief executive officer, effective May 10, according to a filing with Hong Kong Exchange last Friday. The acting CEO Chen Fe
TONGRENTANGCM To Go Ex-Dividend On June 12th, 2024 With 0.33 HKD Dividend Per Share
May 11th - $TONGRENTANGCM(03613.HK)$ is trading ex-dividend on June 12th, 2024. Shareholders of record on June 13th, 2024 will receive 0.33 HKD dividend per share on June 24th, 2024. The ex-divide
Tong Ren Tang Sinopharm (03613) will pay a final dividend of HK$0.33 per share on June 24
According to the Zhitong Finance App, Tong Ren Tang Sinopharm (03613) announced that it will pay a final dividend of HK$0.33 per share for the year ended 31 December 2023 on June 24, 2024.
TONGRENTANGCM: Postponement and Rescheduling of Date of Annual General Meeting and Change of Book Closure Period
Tong Ren Tang Sinopharm (03613.HK) appoints Wang Chi as CEO
Gelonghui, May 10, 丨 Tong Ren Tang Sinopharm (03613.HK) announced that Mr. Wang Chi was appointed as the company's executive director, CEO and member of the Competition Executive Committee, effective May 10, 2024. The board of directors further announced that since Mr. Wang was appointed as the company's CEO, Mr. Chen Fei, executive director, acting CEO and executive deputy general manager of the company will no longer serve as acting CEO. Effective May 10, 2024, he will continue to serve as the company's executive director and executive deputy general manager.
Beijing Tong Ren Tang Gets Nod to Sell Fever Drug in Hong Kong
Beijing Tong Ren Tang Chinese Medicine (HKG:3613), a unit of Tong Ren Tang Technologies (HKG:1666), has obtained approval to sell its drug Danggui Buxue Keli in Hong Kong, a Tuesday filing by the latt
Tong Ren Tang Chinese Medicine (03613.HK): “Angelica Blood Supplement Granules [Tong Ren Tang]” approved for sale in Hong Kong
Gelonghui, April 30, 丨 Tong Ren Tang Chinese Medicine (03613.HK) announced that the company recently received the “Certificate of Registration for Proprietary Chinese Medicines” issued by the Hong Kong Traditional Chinese Medicine Administration, permitting the sale of “Angelica Supplementation Granules [Tong Ren Tang]” in Hong Kong. The relevant information notice is as follows: Drug Name: Angelica Blood Supplementation Granules [Tong Ren Tang]; Registered Holder and Address: Beijing Tong Ren Tang Sinopharm Co., Ltd., No. 3, Da Jing Street, Tai Po Industrial Estate, New Territories, Hong Kong; registration number: HKC-18604; certificate validity period: until April 25, 2029.” The main function of “Angelica Blood Supplementation Granules [Tong Ren Tang]”
Tong Ren Tang Chinese Medicine (03613): Issued a certificate of registration for proprietary Chinese medicines
According to Zhitong Finance App, Tong Ren Tang Sinopharm (03613) issued an announcement. The company recently received the “Certificate of Registration for Proprietary Chinese Medicines” issued by the Hong Kong Traditional Chinese Medicine Administration, which allows the sale of “Angelica Blood Supplementation Granules [Tong Ren Tang]” in Hong Kong.
Express News | Tong Ren Tang: Holding Sun Company obtained the Hong Kong Proprietary Chinese Medicine Registration Certificate for Angelica Blood Supplements
Express News | Tong Ren Tang: Net profit from mother for the first quarter was 576 million yuan, up 10.04% year on year
同仁堂國藥：2023年年報
Express News | The mercury content in Beijing Tongrentang was questioned, and customer service said the production met national standards
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Express News | Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
Express News | Capital Securities: The high dividend rate in the Chinese medicine industry is stable and sustainable
Beijing Tong Ren Tang Chinese Medicine CEO Steps Down; Acting CEO Appointed
Beijing Tong Ren Tang Chinese Medicine (HKG:3613) said Yu Jin resigned as the company's chief executive officer due to personal endeavors, according to a Thursday Hong Kong bourse filing. Chen Fei wil
Tong Ren Tang Sinopharm (03613): Chen Fei appointed as acting CEO
Tong Ren Tang Sinopharm (03613) announced that Yu Jin has resigned as the company's executive director and CEO due to personal matters...
Express News | Beijing Tongrentang Co., Ltd. had a net profit of RMB 1.67 billion for the year.
Tong Ren Tang Sinopharm (3613.HK): Mainland China sales restart and are expected to resume strong growth in 2024
There was a gap in economic recovery, and sales in mainland China declined markedly: the company achieved revenue of HK$1,525 billion for the full year of 2023, a year-on-year decrease of 11.9%. By region, sales revenue in Hong Kong was 100 million Hong Kong dollars, an increase of 10.8%. sea
Analysis
Price Target
No Data
